Podcast appearances and mentions of Edward S Kim

CancerNetwork® collaborated with OncLive® to speak with Edward S. Kim, MD, MBA, and Richard T. Lee, MD, about ongoing initiatives to expand integrative oncology for patients with cancer at City of Hope. Kim is the physician-in-chief and senior vice president at City of Hope Orange County as well as the Construction Industries Alliance City of Hope Orange County physician-in-chief chair. Lee is the Cherng Family Director's Chair of the Center for Integrative Oncology and a medical director of Supportive & Integrative Medicine in the Department of Supportive Care Medicine as well as a clinical professor of Supportive & Integrative Medicine at City of Hope. The discussion partly focused on how integrative oncology is practiced at City of Hope. The institution's style of integrative care derives inspiration from traditional Eastern medicine and encompasses modalities such as acupuncture, meditation, yoga, and massages to help treat patients with cancer more holistically. Lee cited updates in integrative therapy guidelines published by the Society for Integrative Oncology (SIO) in partnership with the American Society of Clinical Oncology (ASCO) to illustrate how integrative care can benefit patient quality of life.1 For example, he highlighted that there was strong evidence in support of implementing mindfulness-based interventions to help reduce anxiety and stress among patients. “These types of integrative therapies are a great way to complement many of the standard-of-care options that we have and provide even further benefit in controlling these symptoms and allowing patients to have a better quality of life as they go through treatment and as they head into survivorship,” Lee said. The conversation also pertained to the institution's efforts to expand the Cherng Family Center for Integrative Oncology, a first-of-its-kind national integrative oncology program, following receipt of a $100 million gift from Andrew and Peggy Cherng, co-founders and co-chief executive officers at Panda Express, supporting its creation.2 This initiative will include conducting rigorous research in a clinical program that may inform future integrative oncology guidelines, pursuing natural product drug development, and instituting educational programs that may train future integrative oncologists. "The only way we're going to be able to increase access to these important programs to more people is to do the rigorous, level 1 research that's needed in order to prove that there is a benefit of any particular area,” Kim said. “Because if we're rigorous and we show the results are positive, then we would expect them to be on the guidelines like the National Comprehensive Cancer Network, and then payers would then provide support to patients who want to have these services.” References 1.        Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. J Clin Oncol. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857 2.        Logsdon Z. City of Hope receives $100 million gift to create first-of-its-kind national integrative oncology program. News release. City of Hope. September 12, 2023. Accessed March 13, 2024. https://tinyurl.com/26y3xj87

In this episode, host Shikha Jain, MD, speaks with Edward Kim, MD about what it means to be a disruptive innovator, how to lead efforts in health care system changes and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Kim 1:19 •    The interview 3:00 •    What was your journey into oncology and the leadership roles you hold now? 3:27 •    Jain and Kim on changing specialties in medical school and in careers 10:45 •    Kim on family, his relationship with his daughter, and their viral Taylor Swift concert video  12:34 •    Jain on the upcoming Healio Disruptive Innovators Awards and how to register 17:46 •    What do you think disruptive innovation means? … Why did you agree to join this initiative? 18:07 •    Jain on framing disruptive innovation as a positive within the struggles of the health care system 23:34  •    How can we get our systems and delivery of health care to reflect the innovation that we see in medical technology advances, cancer care advances and other advances now to disrupt things for the future? 25:02  •    Jain and Kim on perceptions of certain treatments, and how it can prevent forward-thinking innovation 31:36  •    Why do we allow ourselves to fall into that trap in health care? … Why have we taken so many years to start addressing these innovations on a larger scale?  32:54  •    Kim and Jain on risk aversion for physicians and how questioning systems has evolved 37:36 •    If someone could only listen to the few minutes of this episode, what would you want them to take away? 43:02 •    How to contact Kim 44:27 •    Thanks for listening 45:10 Edward S. Kim, M.D., M.B.A., FACP, FASCO, is physician-in-chief and senior vice president, City of Hope Orange County, and vice physician-in-chief and professor, City of Hope National Medical Center.  Learn more about  Healio Disruptive Innovators Awards on June 3, 2023, and how to register.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Kim can be reached via LinkedIn, Facebook, on Twitter @DrEdKim, or via email edwkim@coh.org.  Disclosures:  Jain reports no relevant financial disclosures. Kim reports affiliation with Boerhinger Ingelheim, Genentech and Mirati.

In this episode, Edward S. Kim, MD, MBA, discusses his path to oncology, how he views disruption in health care, and the ways he’s innovating to help both patients and providers. Intro :13 About Kim :22 The interview 2:03 How did you end up in medicine and oncology? 2:20 What do you think it means to have disruptive or innovative health care strategies? 15:24 Oncology care provides the opportunity for disruptive innovation 21:10 How do you decide which risks to take? 25:59 Taking risks can help move the needle forward 37:52 Kim’s take-away from this episode 38:58 How to reach Kim 39:58 Edward S. Kim, MD, MBA, FACP, FASCO, is physician-in-chief at City of Hope Orange County and vice physician-in-chief of City of Hope National Medical Center. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday @ShikhaJainMD. Dr. Kim can be reached by email at edwkim@coh.org and on Twitter @DrEdKim. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Kim reports no relevant financial disclosures.

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expressionChoosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expressionLeveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumabSTK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapyTreatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitorRechallenging after stopping immune checkpoint inhibitor due to immune-related adverse eventsPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:How to approach discordant results with liquid vs tissue biopsiesRepeating NGS testing at progressionSelecting urgent treatment when molecular results are not yet availablePoint mutations in NTRK fusion–positive diseaseSelecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKISelecting first-line and second-line therapy for ROS1-positive diseaseStandard of care for MET-altered diseaseSelecting second-line therapy for RET fusion–positive disease after first-line TKIPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

Guest: Edward S. Kim, MD RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

Guest: Edward S. Kim, MD RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

Guest: Edward S. Kim, MD When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell lung cancer that just might end up in the clinic.

Guest: Edward S. Kim, MD When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell lung cancer that just might end up in the clinic.

Edward S. Kim, MD, of Levine Cancer Institute at Atrium Health in Charlotte, N.C., chats with David H. Henry, MD, host of Blood & Cancer, about how to perform clinical trials in the community oncology setting. Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, discusses a byproduct of our fragmented health care system – patients having to hear the same bad news repeated over and over. Show notes  Only 3%-4% of adult oncology patients are enrolled in clinical trials. Most patients diagnosed with cancer are seen in community settings (as opposed to academic centers). Oncologists in the community setting face significant obstacles to enrolling their patients in clinical trials: Communication between academic and community centers often is lacking, especially in more rural areas of the country. Community-based oncologists usually are not compensated for time spent on research or academic work. Treatment pathways used by many oncologists may not offer any information regarding clinical trials. The traditional infrastructure of a community practice may not have the necessary experts to facilitate clinical trial participation. Community oncologists may not feel comfortable talking to their patients about a novel drug of which they have little knowledge. How can community oncologists facilitate participation in clinical trials? There must be a cultural change, starting with the organization’s leadership. A study coordinator is crucial. Data, finance, and regulatory individuals are likely required. Coordination with pharmacy and pathology usually is necessary. Electronically Accessible Pathways (EAPathways) is a tool developed by Dr. Kim’s team. It is available and allows any oncologist to input a patient’s information to determine if there is an appropriate clinical trial available. Show notes by Sugandha Landy, MD, a resident in the department of internal medicine, University of Pennsylvania, Philadelphia Dr. Kim can be reached at Edward.Kim@atriumhealth.org   Additional reading Patronik KE and ES Kim. A novel clinical pathways approach to delivering regional-based clinical trials and patient care in a hybrid academic- community-based system. J Clin Pathways. 2018 May;4(4):52-5. Ersek JL et al. Implementing precision medicine programs and clinical trials in the community-based oncology practice: Barriers and best practices. Am Soc Clin Oncol Educ Book. 2018 May 23:38:188-96.   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter: @ilanayurkiewicz  

Go online to PeerView.com/GPR860 to view the entire programme with slides. In this activity, an expert in oncology discusses the evolving evidence on molecular testing and treatment of EGFR mutation-positive NSCLC, including new data from real-world studies, and provides practical guidance for nuanced, individualized decision-making related to selection and sequencing of EGFR-targeted therapies throughout the continuum of advanced NSCLC. Upon completion of this activity, participants will be able to: Review the current understanding of the biology of EGFR mutation-based heterogeneity in NSCLC and the clinical roles of EGFR TKIs in the newly diagnosed setting, Assess mechanisms of acquired resistance to EGFR TKIs and their implications for treatment selection in first-line and later lines of therapy in advanced EGFR mutation-positive NSCLC, Discuss real-world evidence on the efficacy and safety of EGFR TKIs and its impact on long-term treatment planning for patients with advanced NSCLC exhibiting EGFR mutations, Employ effective strategies to prevent, mitigate, and manage adverse effects of EGFR TKI therapy to optimize patient outcomes.

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.

In this podcast, Dr. Edward Kim discusses his article, “The Future of Molecular Medicine: Biomarkers, BATTLEs, and Big Data.” Cancer Research News